Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
The cornerstone of the quality ecosystem is the implementation of the Quality Control Orders
Subscribe To Our Newsletter & Stay Updated
